Bioavailability Enhancement Technologies and Services Market by Drug Class, BCS Classification, Bioavailability Enhancement Approach, Dosage Form and Key Geographies : Industry Trends and Global Forecasts, 2022-2035

Bioavailability is known to form an integral part of the drug pharmacokinetics. As a result, over the last couple of years, the concept of bioavailability has garnered significant attention in the pharmaceutical industry. Further, a study conducted on terminated drug development projects revealed that majority of the candidates fail in early phases. The study further highlighted that the aforementioned drug failures can primarily be attributed to the problems associated with pharmacokinetic profiles, ADME (distribution, metabolism, absorption and excretion) properties and toxicity-related concerns. , At present, more than 40% of the marketed drugs are believed to possess low bioavailability, while around 90% of all New Chemical Entities (NCEs), which are being evaluated in pre-clinical and clinical stages of development, exhibit solubility / permeability related issues. Consequently, recent years have seen a rise in drug developers evaluating various re-formulation strategies to improve the bioavailability of existing drugs / drug candidates. In fact, an increasing number of drug candidates have been granted approval via the 505(b)(2) pathway; the aforementioned pathway is used to gain approval for novel formulations consisting of previously approved active pharmaceutical ingredient (API). Additionally, given the shifting focus of drug developers towards development of lipophilic drug compounds, the industry is actively undertaking efforts to identify various bioavailability enhancement techniques, in order to mitigate the challenge of low bioavailability and stability.

In this context, it is also important to mention that a significant number of players engaged in the development of therapeutic interventions currently prefer to outsource their bioavailability enhancement operations to contract service providers. This trend can be attributed to the fact that service providers usually have specialized facilities and equipment, along with established processes, which can help drug developers to accomplish the desired goals in shorter timelines. In order to cater to the requirement for such services, a number of bioavailability enhancement focused service providers for API have been established in the past few years, across various regions of the globe. At present, the bioavailability enhancement service providers are actively trying to consolidate their presence in this field by entering into strategic alliances, to meet the indubitably rising demand for effective therapeutics. For this purpose, substantial mergers and acquisitions have been reported in this market, as service providers strive to become one-stop-shops, to cater to the diverse needs for their clientele. In addition, several stakeholders are engaged in the development of proprietary technologies, based on sustained release principle and bioavailability enhancers, to maintain a competitive edge in this rapidly emerging market. In fact, since 2017, close to 6,000 research articles, evaluating various bioavailability enhancement techniques have been published across several reputed journals. In addition, close to 10,000 patents have been filed, till 2022, providing a significant scientific push for the development of novel approaches. Driven by the increase in number of BCS II and BCS IV molecules being evaluated in early phases of development, the bioavailability enhancement domain is expected to grow at a steady pace in the foreseen future.

SCOPE OF THE REPORT

The "Bioavailability Enhancement Technologies and Services Market (2^nd Edition) by Drug Class (New Drug Approvals and Generics), BCS Classification (BCS II Drugs and BCS IV Drugs), Bioavailability Enhancement Approach (Solid Dispersion, Size Reduction, Lipid-based, and Other Approaches), Dosage Form (Liquids, Solids, Semi-Solids, and Fine Particles) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2022-2035" report features an extensive study of the current market landscape and future potential of the bioavailability enhancement technologies and services market. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in providing bioavailability enhancement technologies and services. Amongst other elements, the report features:

An executive summary of the insights captured in our research. It offers a high-level view on the current state of bioavailability enhancement technologies and services market and its likely evolution in the mid-long term.

A general introduction to bioavailability enhancement, featuring information on the historical overview of bioavailability, assessment of drug bioavailability, need for bioavailability enhancement, and general factors affecting drug bioavailability. Additionally, the chapter includes details on the various types of bioavailability enhancement approaches / technologies employed by various industry stakeholders. The chapter concludes with a discussion on the key growth drivers, as well as upcoming trends in this field.

A detailed assessment of the overall market landscape of bioavailability enhancement service providers, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, bioavailability enhancement principle supported (solubility enhancement, absorption enhancement, sustained release and others), bioavailability enhancement approach employed, including [A] solid dispersion (spray-dried dispersion, hot melt extrusion, polymers, agglomeration / granulation, lyophilization, inclusion complexes, super critical fluid, solvent evaporation and other solid dispersion approaches), [B] size reduction (conversion to nanotechnology-based formulation, high pressure homogenization / mirconization, bead layering, microfluidics, and other miscellaneous size reduction approach), [C] lipid-based (liposomes, self-emulsifying drug delivery system, excipients, micelles, lipid-nanotechnology based formulations and other lipid-based formulations), and other bioavailability enhancement approaches (co-crystallization, chemical modification, and other miscellaneous bioavailability enhancement technologies), type of dosage form supported (solids, liquids, fine particles and semi-solids), and route of administration of drug product (oral, topical, parenteral and others).

A detailed assessment of the current market landscape of bioavailability enhancement technology providers, featuring analysis based on several parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters. In addition, the chapter highlights an in-depth analysis of various bioavailability enhancement technologies based on bioavailability enhancement principle supported (solubility enhancement, absorption enhancement, sustained release, and others), bioavailability enhancement approach employed (solid dispersion, nanotechnology, lipid-based, other size reduction, chemical modification, and others), type of molecule (small molecules and biologics), type of dosage form supported (solids, liquids, fine particles, and semi-solids), route of administration (oral, topical, parenteral, and others), availability for license and associated intellectual property rights.

An in-depth analysis, highlighting the contemporary market trends, using six schematic representations, including [A] a world map representation depicting the region-wise distribution of various stakeholders engaged in offering bioavailability enhancement services, on the basis of their company size, [B] a waffle chart representation, highlighting the regional distribution of bioavailability enhancement service providers, based on various types of bioavailability enhancement approaches employed by them, [C] a heat map representation of bioavailability enhancement service providers, based on bioavailability enhancement approaches and type of dosage form, [D] a horizontally grouped bar chart, highlighting the distribution of bioavailability enhancement service providers based on their company size and type of bioavailability enhancement principles, [E] an insightful tree map representation of bioavailability enhancement service providers (in terms of bioavailability enhancement principles employed and bioavailability enhancement approaches offered), as well as [F] a 3D bubble analysis comparing the key players engaged in this domain, based on several relevant parameters (such as year of establishment, company size, number of bioavailability enhancement approaches offered and region).

Elaborate profiles of various prominent players that are engaged in offering bioavailability enhancement technologies and services. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), details related to its financial performance (if available), bioavailability enhancement services portfolio, recent developments and an informed future outlook.

A company benchmarking analysis of various players engaged in this domain. It highlights the capabilities of industry players in terms of their expertise across various services related to bioavailability enhancement of drug compounds and / or drug candidates. The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to gain a competitive edge in the industry.

An analysis of partnerships that have been inked between several stakeholders engaged in providing bioavailability enhancement services and technologies, during the period 2013-2022, covering mergers and acquisitions, licensing agreements, alliances, product development and manufacturing agreements, research and development agreements, product development and commercialization agreements, service agreements, and other agreements.

A detailed review of more than 5,800 peer-reviewed, scientific articles related to research on bioavailability enhancement of drug compounds and / or drug candidates, based on parameters, such as year of publication, type of publication and popular keywords. The chapter also provides information on top journals, top publishers and top copyright holders (in terms of number of articles published)

An in-depth analysis of the patents that have been filed / granted for bioavailability enhancement approaches and technologies since 2003, based on important parameters, such as type of patent, patent application year, patent publication year, bioavailability enhancement approach, CPC symbols, geography, emerging focus area, type of organization, leading industry and non-industry players (in terms of number of patents filled / granted), and individual patent assignees (in terms of size of intellectual property portfolio). The chapter also includes an insightful benchmarking and valuation analysis.

An in-depth analysis of completed, ongoing, and planned clinical studies related to bioavailability enhancement of various drug compounds and / or candidates, based on several relevant parameters, such as trial registration year, trial phase, current recruitment status, enrolled patient population, study design, type of sponsor / collaborator, leading industry and non-industry players (in terms of number of registered trials conducted), type of molecule and key geographies.

An elaborate analysis in order to estimate the current and future demand for bioavailability enhancement technologies and services, based on several relevant parameters, such as drug class (new drug approvals and generics), BCS classification (BCS II drugs and BCS IV drugs) and dosage form (liquids, solids, semi-solids, and fine particles / powders) for the period 2022-2035. Kindly note that input parameters considered for this analysis include number of New Chemical Entity (NCE) candidates and generic / reformulated drug products that are likely to undergo formulation development over the period of next 13 years.

A detailed market forecast analysis, highlighting the likely evolution of the bioavailability enhancement services market in the short to mid-term and long term, over the period 2022-2035. Further, the year-wise projections of the current and future opportunity have been segmented based on relevant parameters, such as drug class (new drug approvals and generics), BCS classification (BCS II drugs and BCS IV drugs), bioavailability enhancement approach (solid dispersion, size reduction, and lipid-based), dosage form (liquids, solids, semi-solids, an fine particles / powders) and key geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, which represent different tracks of the industry's growth.

An insightful framework evaluating the bioavailability enhancement approaches based on various parameters, such as number of technologies, number of approved drugs, trends highlighted in published literature and patents, and business models adopted by industry stakeholders. It also provides a value addition matrix for respective bioavailability enhancement approaches currently employed by stakeholders.

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary research. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary sources of information.

KEY QUESTIONS ANSWERED:

Who are the key players engaged in the bioavailability enhancement technologies and services market?

Which are the key geographies where bioavailability enhancement technology and service providers are located?

What are the recent developments and expected trends in the bioavailability enhancement industry?

Which partnership models are commonly adopted by stakeholders offering bioavailability enhancement solutions?

What is the evolving trend of publications focused on bioavailability enhancement technologies?

Which companies are actively filing patents to drive innovation in the bioavailability enhancement market?

What are the key market trends and driving factors that are likely to impact the growth of the bioavailability enhancement technologies and services market?

How is the current and future opportunity likely to be distributed across key market segment?

CHAPTER OUTLINES

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of bioavailability enhancement technologies and services market and its likely evolution in the mid-long term.

Chapter 3 provides a general introduction to bioavailability enhancement, featuring information on the historical overview of bioavailability, assessment of drug bioavailability, need for bioavailability enhancement, and general factors affecting drug bioavailability. Additionally, the chapter includes details on the various types of bioavailability enhancement approaches / technologies employed by various industry stakeholders. The chapter concludes with a discussion on the key growth drivers, as well as upcoming trends in this field.

Chapter 4 provides a detailed review of the overall market landscape of bioavailability enhancement service providers, along with the information on their year of establishment, company size (in terms of number of employees), location of headquarters, bioavailability enhancement principle supported (solubility enhancement, absorption enhancement, sustained release and others), bioavailability enhancement approach employed, including [A] solid dispersion (spray-dried dispersion, hot melt extrusion, polymers, agglomeration / granulation, lyophilization, inclusion complexes, super critical fluid, solvent evaporation and other solid dispersion approaches), [B] size reduction (conversion to nanotechnology-based formulation, high pressure homogenization / micronization, bead layering, microfluidics, and other miscellaneous size reduction approach), [C] lipid-based (liposomes, self-emulsifying drug delivery system, excipients, micelles, lipid-nanotechnology based formulations and other lipid-based formulations), and other bioavailability enhancement approaches (co-crystallization, chemical modification, and other miscellaneous bioavailability enhancement technologies), type of dosage form supported (solids, liquids, fine particles and semi-solids), and route of administration of drug product (oral, topical, parenteral and others).

Chapter 5 provides a detailed assessment of the current market landscape of bioavailability enhancement technology providers, featuring information on their year of establishment, company size (in terms of employee count) and location of headquarters. In addition, the chapter highlights an in-depth analysis of various bioavailability enhancement technologies based on bioavailability enhancement principle supported (solubility enhancement, absorption enhancement, sustained release, and others), bioavailability enhancement approach employed (solid dispersion, nanotechnology, lipid-based, other size reduction, chemical modification, and others), type of molecule (small molecules and biologics), type of dosage form supported (solids, liquids, fine particles, and semi-solids), route of administration (oral, topical, parenteral, and others), availability for license and associated intellectual property rights.

Chapter 6 provides an analysis, highlighting the contemporary market trends through six schematic representations, including a world map representation depicting the region-wise distribution of various stakeholders engaged in offering bioavailability enhancement services, on the basis of their company size, a waffle chart representation, highlighting the regional distribution of bioavailability enhancement service providers, based on various types of bioavailability enhancement approaches employed by them, a heat map representation of bioavailability enhancement service providers, based on bioavailability enhancement approaches and type of dosage form, a horizontally grouped bar chart, highlighting the distribution of bioavailability enhancement service providers based on their company size and type of bioavailability enhancement principles, an insightful tree map representation of bioavailability enhancement service providers (in terms of bioavailability enhancement principles employed and bioavailability enhancement approaches offered), as well as a 3D bubble analysis comparing the key players engaged in this domain, based on several relevant parameters (such as year of establishment, company size, number of bioavailability enhancement approaches offered and region).

Chapter 7 includes detailed profiles of various prominent players (identified on the basis of the breadth of their respective service and technology portfolios as well as their partnership activity) engaged in offering bioavailability enhancement services. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), details related to its financial performance (if available), bioavailability enhancement services portfolio, recent developments and an informed future outlook.

Chapter 8 presents a company benchmarking analysis of various players engaged in this domain. It highlights the capabilities of industry players (in terms of their expertise across various services related to bioavailability enhancement of drug compounds and / or drug candidates). The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to gain a competitive edge in the industry.

Chapter 9 features an elaborate discussion and analysis of various collaborations and partnerships that have been inked amongst players in this market, during the period 2013-2022. Further, the partnership activity in this domain has been analyzed based on various parameters, such as year of partnership, type of partnership (such as mergers and acquisition, licensing agreements, alliances, product development and manufacturing agreements, research and development agreements, product development and commercialization agreements, service agreements, and other agreements), and regional distribution of the collaborations.

Chapter 10 presents a detailed review of 5,800+ peer-reviewed, scientific articles related to research on bioavailability enhancement of drug compounds and / or drug candidates, based on parameters, such as year of publication, type of publication and popular keywords. The chapter also provides information on the top journals, top publishers and top copyright holders (in terms of number of articles published)

Chapter 11 provides an in-depth analysis of the nearly 10,000 patents filed / granted related to bioavailability enhancement approaches and technologies since 2003, based on important parameters, such as type of patent, patent application year, patent publication year, bioavailability enhancement approach, CPC symbols, geography, emerging focus area, type of organization, leading industry and non-industry players (in terms of number of patents filled / granted), and individual patent assignees (in terms of size of intellectual property portfolio). The chapter also includes an insightful benchmarking and valuation analysis.

Chapter 12 presents a detailed analysis of completed, ongoing, and planned clinical studies related to bioavailability enhancement of various drug compounds and / or candidates, based on several relevant parameters, such as trial registration year, trial phase, current recruitment status, enrolled patient population, study design, type of sponsor / collaborator, leading industry and non-industry players (in terms of number of registered trials conducted), type of molecule and key geographies.

Chapter 13 includes an elaborate analysis in order to estimate the current and future demand for bioavailability enhancement technologies and services, based on several relevant parameters, such as drug class (new drug approvals and generics), BCS classification (BCS II drugs and BCS IV drugs) and dosage form (liquids, solids, semi-solids, and fine particles /powders) for the period 2022-2035. Kindly note that input parameters considered for this analysis include number of New Chemical Entity (NCE) candidates and generic / reformulated drug products that are likely to undergo formulation development over the period of next 13 years.

Chapter 14 presents an insightful market forecast analysis, highlighting the future potential of the spatial genomics, transcriptomics, and proteomics solutions market, till 2035. In order to provide a detailed future outlook, our projections have been segmented across different segments on the basis of [A] drug class (new drug approvals and generics), [B] BCS classification (BCS II drugs and BCS IV drugs), [C] bioavailability enhancement approach (solid dispersion, size reduction, lipid-based, and other approaches), [D] dosage form (liquids, solids, semi-solids, and fine particles) and [E] key geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World).

Chapter 15 features an insightful framework evaluating the bioavailability enhancement approaches based on various parameters, such as number of technologies, number of approved drugs, trends highlighted in published literature and patents, and business models adopted by industry stakeholders. Further, it also provides a value addition matrix for respective bioavailability enhancement approaches currently employed by stakeholders.

Chapter 16 presents the summary of the overall report. Additionally, in this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Product Code: RA100393

1. PREFACE

1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Historical Overview of Bioavailability
3.3. Assessment of Drug Bioavailability
- 3.3.1. Key Considerations for Bioavailability and Assessment Studies
  - 3.3.1.1. Absolute Bioavailability
  - 3.3.1.2. Relative Bioavailability
  - 3.3.1.3. Single and Multiple Dose Studies
- 3.3.2. Studies in Healthy Subjects and Patients
  - 3.3.2.1. Different Bioavailability Assessment methods
3.4. Need for Bioavailability Enhancement
3.5. Factors Affecting Bioavailability
- 3.5.1. Drug Related Factors
- 3.5.2. Patient Physiology Related Factors
3.6. Bioavailability Enhancement Technologies
- 3.6.1. Physical Technologies for Bioavailability Enhancement
  - 3.6.1.1. Solid Dispersion
    - 3.6.1.1.1. Classification of Solid Dispersion Approaches
    - 3.6.1.1.2. Methodologies for Solid Dispersion Approaches
      - 3.6.1.1.2.1. Hot Melt Extrusion
      - 3.6.1.1.2.2. Melting / Fusion Methods
      - 3.6.1.1.2.3. Solvent Evaporation
      - 3.6.1.1.2.4. Spray-Dried Dispersion
      - 3.6.1.1.2.5. Other Techniques Used for Solid Dispersion
  - 3.6.1.2. Nanosuspension Technology
    - 3.6.1.2.1. Top-Down Approach
    - 3.6.1.2.2. Bottom-Up Approach
  - 3.6.1.3. Chemical Technologies for Bioavailability Enhancement
    - 3.6.1.3.1. Lipid-Based Formulations
    - 3.6.1.3.2. Non-Metal-Based Drug Delivery Systems
    - 3.6.1.3.3. Polymer-Based Drug Delivery Systems
  - 3.6.1.4. Biological Technologies for Bioavailability Enhancement
3.7. Concluding remarks

4. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT SERVICE PROVIDERS

4.1. Chapter Overview
4.2. Bioavailability Enhancement Service Providers: Overall Market Landscape
- 4.2.1. Analysis by Year of Establishment
- 4.2.2. Analysis by Company Size
- 4.2.3. Analysis by Location of Headquarters
- 4.2.4. Analysis by Bioavailability Enhancement Principle
- 4.2.5. Analysis by Bioavailability Enhancement Approach
  - 4.2.5.1. Analysis by Solid Dispersion Approaches
  - 4.2.5.2. Analysis by Size Reduction Approaches
  - 4.2.5.3. Analysis by Lipid-Based Approaches
  - 4.2.5.4. Analysis by Other Bioavailability Enhancement Approaches
- 4.2.6. Analysis by Dosage Form
- 4.2.7. Analysis by Route of Administration

5. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT TECHNOLOGY PROVIDERS

5.1. Chapter Overview
5.2. Bioavailability Enhancement Technologies: Technology Providers Landscape
- 5.2.1. Analysis by Year of Establishment
- 5.2.2. Analysis by Company Size
- 5.2.3. Analysis by Location of Headquarters
- 5.2.4. Analysis by Company Size and Location of Headquarters
- 5.2.5. Leading Players: Analysis by Number of Technologies
5.3. Bioavailability Enhancement Technologies: Market Landscape
- 5.3.1. Analysis by Bioavailability Enhancement Principle
- 5.3.2. Analysis by Bioavailability Enhancement Approach
- 5.3.3. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
- 5.3.4. Analysis by Type of Molecule
- 5.3.5. Analysis by Bioavailability Enhancement Approach and Type of Molecule
- 5.3.6. Analysis by Dosage Form
- 5.3.7. Analysis by Route of Administration
- 5.3.8. Analysis by Availability for License
- 5.3.9. Analysis by Intellectual Property Rights

6. KEY INSIGHTS

6.1. Chapter Overview
- 6.1.1. Analysis by Company Size and Location of Headquarters (World Map Representation)
- 6.1.2. Analysis by Location of Headquarters and Bioavailability Enhancement Approach (Waffle Chart)
- 6.1.3. Analysis by Bioavailability Enhancement Approach and Dosage Form (Heatmap Representation)
- 6.1.4. Analysis by Company Size and Bioavailability Enhancement Principle (Horizontally Grouped Bar Chart)
- 6.1.5. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach (Tree map Representation)
- 6.1.6. Analysis by Year of Establishment, Company Size, Number of Bioavailability Enhancement Approaches Offered and Region (3D Bubble Chart)

7. COMPANY PROFILES

7.1. Chapter Overview
7.2. Adare Pharma Solutions
- 7.2.1. Company Overview
- 7.2.2. Financial Overview
- 7.2.3. Bioavailability Enhancement Services Portfolio
- 7.2.4. Recent Developments and Future Outlook
7.3. Ascendia Pharmaceuticals
- 7.3.1. Company Overview
- 7.3.2. Financial Overview
- 7.3.3. Bioavailability Enhancement Services Portfolio
- 7.3.4. Recent Developments and Future Outlook
7.4. Catalent
- 7.4.1. Company Overview
- 7.4.2. Financial Overview
- 7.4.3. Bioavailability Enhancement Services Portfolio
- 7.4.4. Recent Developments and Future Outlook
7.5. Formulex Pharma Innovations (formerly SoluBest)
- 7.5.1. Company Overview
- 7.5.2. Financial Overview
- 7.5.3. Bioavailability Enhancement Services Portfolio
- 7.5.4. Recent Developments and Future Outlook
7.6. Lonza
- 7.6.1. Company Overview
- 7.6.2. Financial Overview
- 7.6.3. Bioavailability Enhancement Services Portfolio
- 7.6.4. Recent Developments and Future Outlook
7.7. Lubrizol Life Science Health
- 7.7.1. Company Overview
- 7.7.2. Financial Overview
- 7.7.3. Bioavailability Enhancement Services Portfolio
- 7.7.4. Recent Developments and Future Outlook
7.8. Pace Analytical
- 7.8.1. Company Overview
- 7.8.2. Financial Overview
- 7.8.3. Bioavailability Enhancement Services Portfolio
- 7.8.4. Recent Developments and Future Outlook
7.9. Quotient Sciences
- 7.9.1. Company Overview
- 7.9.2. Financial Overview
- 7.9.3. Bioavailability Enhancement Services Portfolio
- 7.9.4. Recent Developments and Future Outlook
7.10. WuXi STA (A Subsidiary of WuXi AppTec)
- 7.10.1. Company Overview
- 7.10.2. Financial Overview
- 7.10.3. Bioavailability Enhancement Services Portfolio
- 7.10.4. Recent Developments and Future Outlook

8. COMPANY BENCHMARK ANALYSIS

8.1. Chapter Overview
8.2. Company Benchmarking Analysis: Methodology
8.3. Company Benchmarking Analysis: Peer Groups
- 8.3.1. Benchmarking of Players based in North America, Established Pre 2000 (Peer Group I)
- 8.3.2. Benchmarking of Players based in North America, Established 2000-2010 (Peer Group II)
- 8.3.3. Benchmarking of Players based in North America, Established Post 2010 (Peer Group III)
- 8.3.4. Benchmarking of Players based in Europe, Established Pre 2000 (Peer Group IV)
- 8.3.5. Benchmarking of Players based in Europe, Established 2000-2010 (Peer Group V)
- 8.3.6. Benchmarking of Players based in Europe, Established Post 2010 (Peer Group VI)
- 8.3.7. Benchmarking of Players based in Asia and Rest of the World, Established Pre 2000 (Peer Group VII)
- 8.3.8. Benchmarking of Players based in Asia and Rest of the World, Established Post 2000 (Peer Group VIII)

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview
9.2. Partnership Models
9.3. Bioavailability Enhancement: Partnerships and Collaborations
- 9.3.1. Analysis by Year of Partnership
- 9.3.2. Analysis by Type of Partnership
- 9.3.3. Analysis by Year and Type of Partnership
- 9.3.4. Analysis by Type of Partner
- 9.3.5. Analysis by Type of Partnership and Type of Partner
- 9.3.6. Most Active Players: Analysis by Number of Partnerships
9.4. Analysis by Geography
- 9.4.1. Analysis by Region
- 9.4.2. Analysis by Country
- 9.4.3. Analysis by Type of Partnership and Location of Partner Headquarters

10. PUBLICATION ANALYSIS

10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Bioavailability Enhancement: Publication Analysis
- 10.3.1. Analysis by Year of Publication
- 10.3.2. Analysis by Type of Publication
- 10.3.3. Analysis by Type of Bioavailability Enhancement Approach
- 10.3.4. Analysis by Year of Publication and Type of Bioavailability Enhancement Approach
- 10.3.5. Most Popular Journals: Analysis by Number of Publications
- 10.3.6. Most Popular Journals: Analysis of Journal Impact Factor
- 10.3.7. Most Popular Publishers: Analysis by Number of Publications
- 10.3.8. Most Popular Copyright Holders: Analysis by Number of Publications
- 10.3.9. Analysis by Popular Keywords

11. PATENT ANALYSIS

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Bioavailability Enhancement: Patent Analysis
- 11.3.1. Analysis by Application Year
- 11.3.2. Analysis by Publication Year
- 11.3.3. Analysis by Bioavailability Enhancement Approach
- 11.3.4. Analysis by CPC Symbols
- 11.3.5. Analysis by Geography
- 11.3.6. Analysis by Emerging Focus Areas
- 11.3.7. Analysis by Type of Organization
- 11.3.8. Leading Players: Analysis by Number of Patents
11.4. Bioavailability Enhancement Market: Patent Benchmarking Analysis
- 11.4.1. Analysis by Patent Characteristics
11.5. Bioavailability Enhancement Market: Patent Valuation Analysis
11.6. Leading Patents: Analysis by Number of Citations

12. CLINICAL TRIAL ANALYSIS

12.1. Chapter Overview
12.2. Guidelines To Conduct Bioavailability Studies
12.3. Bioavailability Enhancement: Clinical Trials Analysis
- 12.3.1. Research Methodology
- 12.3.2. Analysis of Trials by Trial Registration Year
- 12.3.3. Analysis of Enrolled Patient Population by Trial Registration Year
- 12.3.4. Analysis of Trials by Study Design
- 12.3.5. Analysis of Trials by Trial Phase
- 12.3.6. Analysis of Trials by Trial Recruitment Status
- 12.3.7. Analysis of Trials by Type of Sponsor / Collaborator
- 12.3.8. Analysis by Type of Molecule and Trial Phase
- 12.3.9. Leading Industry Players: Analysis by Number of Registered Trials
- 12.3.10. Leading Non-Industry Players: Analysis by Number of Registered Trials
- 12.3.11. Analysis by Study Focus
- 12.3.12. Analysis of Trials by Geography
- 12.3.13. Analysis of Enrolled Patient Population by Geography

13. DEMAND ANALYSIS

13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Global Demand for Bioavailability Enhancement Technologies and Services, 2022-2035
13.4. Analysis by Drug Class, 2022 and 2035
- 13.4.1. Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, 2022-2035
- 13.4.2. Demand for Bioavailability Enhancement Technologies and Services for Generics, 2022-2035
13.5. Analysis by BCS Classification, 2022 and 2035
- 13.5.1. Demand for Bioavailability Enhancement Technologies and Services for BCS II Drugs, 2022-2035
- 13.5.2. Demand for Bioavailability Enhancement Technologies and Services for BCS IV Drugs, 2022-2035
13.6. Analysis by Dosage, 2022 and 2035
- 13.6.1. Demand for Bioavailability Enhancement Technologies and Services for Liquids, 2022-2035
- 13.6.2. Demand for Bioavailability Enhancement Technologies and Services for Solids, 2022-2035
- 13.6.3. Demand for Bioavailability Enhancement Technologies and Services for Semi- Solids, 2022-2035
- 13.6.4. Demand for Bioavailability Enhancement Technologies and Services for Fine Particles / Powders, 2022-2035
- 13.6.5. Demand for Bioavailability Enhancement Technologies and Services for Other Dosage Forms, 2022-2035
13.7. Concluding Remarks

14. MARKET FORECAST AND OPPURTUNITY ANALYSIS

14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Global Bioavailability Enhancement Services Market, 2022-2035
14.4. Bioavailability Enhancement Services Market: Analysis by Drug Class, 2022 and 2035
- 14.4.1. Bioavailability Enhancement Services Market for New Drug Approvals, 2022- 2035
- 14.4.2. Bioavailability Enhancement Services Market for Generics, 2022-2035
14.5. Bioavailability Enhancement Services Market: Analysis by BCS Classification, 2022 and 2035
- 14.5.1. Bioavailability Enhancement Services Market for BCS II Drugs, 2022-2035
- 14.5.2. Bioavailability Enhancement Services Market for BCS IV Drugs, 2022-2035
14.6. Bioavailability Enhancement Services Market: Analysis by Bioavailability Enhancement Approach, 2022 and 2035
- 14.6.1. Bioavailability Enhancement Services Market for Lipid Based Approaches, 2022-2035
- 14.6.2. Bioavailability Enhancement Services Market for Size Reduction Based Approaches, 2022-2035
- 14.6.3. Bioavailability Enhancement Services Market for Solid Dispersion Based Approaches, 2022-2035
- 14.6.4. Bioavailability Enhancement Services Market for Other Bioavailability Enhancement Approaches, 2022-2035
14.7. Bioavailability Enhancement Services Market: Analysis by Dosage Form, 2022 and 2035
- 14.7.1. Bioavailability Enhancement Services Market for Liquids, 2022-2035
- 14.7.2. Bioavailability Enhancement Services Market for Solids, 2022-2035
- 14.7.3. Bioavailability Enhancement Services Market for Semi-Solids, 2022-2035
- 14.7.4. Bioavailability Enhancement Services Market for Fine Particles / Powders, 2022-2035
- 14.7.5. Bioavailability Enhancement Services Market for Other Dosage Forms, 2022- 2035
14.8. Bioavailability Enhancement Services Market: Analysis by Key Geographies, 2022 and 2035
- 14.8.1. Bioavailability Enhancement Services Market in North America, 2022-2035
- 14.8.2. Bioavailability Enhancement Services Market in Europe, 2022-2035
- 14.8.3. Bioavailability Enhancement Services Market in Asia, 2022-2035
- 14.8.4. Bioavailability Enhancement Services Market in Latin America, 2022-2035
- 14.8.5. Bioavailability Enhancement Services Market in Middle East and North Africa, 2022-2035
- 14.8.6. Bioavailability Enhancement Services Market in Rest of the World, 2022-2035
14.9. Concluding Remarks

15. TECHNOLOGY EVALUATION FRAMEWORK

15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Technologies based on Solid Dispersion Approaches
- 15.3.1 List of Approved Drugs
- 15.3.2 Trends in Intellectual Capital
- 15.3.3. Trends in Research Activity
- 15.3.4. Business Model Adopted by Developers
15.4. Technologies based on Size Reduction Approaches
- 15.4.1 List of Approved Drugs
- 15.4.2 Trends in Intellectual Property
- 15.4.3. Trends in Research Activity
- 15.3.4. Business Model Adopted by Developers
15.5. Technologies based on Lipid-based Approaches
- 15.5.1 List of Approved Drugs
- 15.5.2 Trends in Intellectual Property
- 15.5.3. Trends in Research Activity
- 15.3.4. Business Model Adopted by Developers
15.6. Technology Evaluation Framework: Wind Rose Representation
15.7. Technology Evaluation Framework: Spider Web Representation
15.8. Results and Discussions

16. CONCLUSION

17. APPENDIX I: LIST OF COMPANIES

18. APPENDIX II: TABULATED DATA